Ovarian Cancer Stocks

Biotechnology firms in this sector focus on overcoming the high recurrence rates and late-stage diagnosis challenges inherent in gynecological malignancies through targeted therapies, molecular diagnostics, and protein-based drug delivery systems.

As of Oct 23, 2026, Ovarian Cancer has 8 US-listed companies worth $4.2B combined. The median member moved +9.9% over the past week; IMNN led at +21.1% and GNLX trailed at -17.4%.